Abundance Wealth Counselors Boosts Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Abundance Wealth Counselors grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,529 shares of the company’s stock after purchasing an additional 528 shares during the period. Abundance Wealth Counselors’ holdings in TransMedics Group were worth $345,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Clear Creek Financial Management LLC purchased a new stake in TransMedics Group in the 4th quarter worth about $352,000. Perigon Wealth Management LLC raised its stake in TransMedics Group by 212.4% in the fourth quarter. Perigon Wealth Management LLC now owns 14,277 shares of the company’s stock worth $828,000 after buying an additional 9,707 shares in the last quarter. Sachetta LLC purchased a new position in TransMedics Group in the fourth quarter valued at about $40,000. Cornerstone Wealth Management LLC purchased a new stake in TransMedics Group during the fourth quarter valued at approximately $231,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of TransMedics Group in the 4th quarter worth $239,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Up 0.9 %

TMDX stock opened at $67.55 on Friday. The firm has a 50 day simple moving average of $67.28 and a 200 day simple moving average of $112.27. The firm has a market cap of $2.27 billion, a PE ratio of 71.86 and a beta of 2.12. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

Insider Activity

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMDX. Oppenheimer restated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Robert W. Baird decreased their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.